Relationship Between Systemic Immune-Inflammation Index and Irritable Bowel Syndrome

Güven, İbrahim Ethem; Başpınar, Batuhan; Atalay, Roni

doi:10.5152/tjg.2021.21321

Cited by 9 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study on moyamoya patients demonstrated elevated SII levels in both acute and chronic phases of the disease [ 11 ]. Similarly, in a study on patients with inflammatory bowel disease, significantly higher SII levels were found [ 12 ]. Consistent with these findings, our study also showed increased SII in SLE patients compared to the control group, indicating systemic inflammation associated with this autoimmune disease.…”

Section: Discussionmentioning

confidence: 86%

Systemic Immune-Inflammation Index as a Potential Biomarker for Assessing Disease Activity and Predicting Proteinuria Development in Systemic Lupus Erythematosus

Ergun,

Aktas,

Sahin

et al. 2024

Cureus

View full text Add to dashboard Cite

Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease with varied clinical manifestations affecting multiple organ systems. This study aimed to investigate the association between the systemic immune-inflammation index (SII) and disease activity, as well as proteinuria levels in patients with SLE. Methodology A total of 141 patients diagnosed with SLE and 99 control subjects were included in this retrospective study. SLE patients were divided into two groups based on the presence (52) or absence (89) of proteinuria. Demographic data, laboratory parameters, and disease activity scores were recorded. SII was calculated based on peripheral blood counts. Statistical analysis was performed to assess the relationship between SII levels and disease activity, as well as proteinuria. Results The statistical analysis among the three groups revealed that SII was significantly different in all three groups (p < 0.001). Moreover, within the SLE cohort, patients with proteinuria had significantly higher SII levels compared to those without proteinuria (p = 0.012). Correlation analysis revealed a positive association between SII and both proteinuria and Systemic Lupus Erythematosus Disease Activity Index 2000 (r = 0.215; p = 0.011 and r = 0.186; p = 0.028, respectively). Receiver operating characteristic analysis demonstrated that SII had potential clinical value in diagnosing SLE and predicting proteinuria development. Conclusions The findings of this study suggest that SII may serve as a useful biomarker for assessing disease activity and predicting proteinuria development in patients with SLE. Further research is warranted to validate these findings and explore the utility of SII in clinical practice for monitoring disease progression and treatment response in SLE.

show abstract

Section: Discussionmentioning

confidence: 86%

Systemic Immune-Inflammation Index as a Potential Biomarker for Assessing Disease Activity and Predicting Proteinuria Development in Systemic Lupus Erythematosus

Ergun,

Aktas,

Sahin

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…SII is a new, inexpensive biomarker that can be easily calculated using platelet, neutrophil, and lymphocyte counts, showing a balance between inflammation and immune response ( 21 , 24 , 25 ). At present, SII shows very high reliability in reacting to the body's immune-inflammation state in a plurality of diseases, such as predicting tumor recurrence and activity of ankylosing spondylitis, as well as bell palsy and irritable bowel syndrome ( 50 – 53 ). Interestingly, the systemic immune-inflammation index was also associated with increased carotid intima-media thickness in hypertensive patients ( 54 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical value of the systemic immune-inflammation index in moyamoya disease

Liu

Jin

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

BackgroundMoyamoya disease (MMD) is a rare cerebrovascular disorder with unknown etiology. The underlying pathophysiological mechanism of moyamoya disease remains to be elucidated, but recent studies have increasingly highlighted that abnormal immune response may be a potential trigger for MMD. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) are inflammatory markers that can reflect the immune-inflammation state of the disease.ObjectiveThe purpose of this study was to investigate SII, NLR, and PLR in patients with moyamoya disease.MethodsA total of 154 patients with moyamoya disease (MMD group) and 321 age- and sex-matched healthy subjects (control group) were included in this retrospective case–control study. Complete blood count parameters were assayed to calculate the SII, NLR, and PLR values.ResultsThe SII, NLR, and PLR values in the moyamoya disease group were significantly higher than those in the control group [754 ± 499 vs. 411 ± 205 (P < 0.001), 2.83 ± 1.98 vs. 1.81 ± 0.72 (P < 0.001), and 152 ± 64 vs. 120 ± 42 (P < 0.001), respectively]. The SII in the medium-moyamoya vessels of moyamoya disease was higher than that in the high-moyamoya vessels and low-moyamoya vessels (P = 0.005). Using the receiver operating characteristic (ROC) curve analysis to predict MMD, the highest area under the curve (AUC) was determined for SII (0.76 for SII, 0.69 for NLR, and 0.66 for PLR).ConclusionBased on the results of this study, patients with moyamoya disease admitted for inpatient care due to acute or chronic stroke have significantly higher SII, NLR, and PLR when compared to blood samples drawn from completely healthy controls in a non-emergent outpatient setting. While the findings may suggest that inflammation plays a role in moyamoya disease, further studies are warranted to corroborate such an association. In the middle stage of moyamoya disease, there may be a more intense imbalance of immune inflammation. Further studies are needed to determine whether the SII index contributes to the diagnosis or serves as a potential marker of an inflammatory response in patients with moyamoya disease.

show abstract

“…The etiology and progression of IBS involve complex, multifactorial processes that are not yet fully comprehended[ 3 ]. Emerging research has provided novel insights into the pathophysiology of IBS, with hypotheses spanning intestinal immunity, the brain-gut-microbiota axis[ 4 ], visceral hypersensitivity, intestinal dysbiosis[ 5 ], inflammation[ 6 ], post-infectious factors[ 7 ], food sensitivities[ 8 ], genetic factors[ 9 ], and psychosocial dysfunctions[ 10 ]. These insights have spurred the development of a variety of therapeutic strategies.…”

Section: Introductionmentioning

confidence: 99%

Immune cell signatures and causal association with irritable bowel syndrome: A mendelian randomization study

Chai,

Ma,

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND The mucosal barrier's immune-brain interactions, pivotal for neural development and function, are increasingly recognized for their potential causal and therapeutic relevance to irritable bowel syndrome (IBS). Prior studies linking immune inflammation with IBS have been inconsistent. To further elucidate this relationship, we conducted a Mendelian randomization (MR) analysis of 731 immune cell markers to dissect the influence of various immune phenotypes on IBS. Our goal was to deepen our understanding of the disrupted brain-gut axis in IBS and to identify novel therapeutic targets. AIM To leverage publicly available data to perform MR analysis on 731 immune cell markers and explore their impact on IBS. We aimed to uncover immunophenotypic associations with IBS that could inform future drug development and therapeutic strategies. METHODS We performed a comprehensive two-sample MR analysis to evaluate the causal relationship between immune cell markers and IBS. By utilizing genetic data from public databases, we examined the causal associations between 731 immune cell markers, encompassing median fluorescence intensity, relative cell abundance, absolute cell count, and morphological parameters, with IBS susceptibility. Sensitivity analyses were conducted to validate our findings and address potential heterogeneity and pleiotropy. RESULTS Bidirectional false discovery rate correction indicated no significant influence of IBS on immunophenotypes. However, our analysis revealed a causal impact of IBS on 30 out of 731 immune phenotypes (P < 0.05). Nine immune phenotypes demonstrated a protective effect against IBS [inverse variance weighting (IVW) < 0.05, odd ratio (OR) < 1], while 21 others were associated with an increased risk of IBS onset (IVW ≥ 0.05, OR ≥ 1). CONCLUSION Our findings underscore a substantial genetic correlation between immune cell phenotypes and IBS, providing valuable insights into the pathophysiology of the condition. These results pave the way for the development of more precise biomarkers and targeted therapies for IBS. Furthermore, this research enriches our comprehension of immune cell roles in IBS pathogenesis, offering a foundation for more effective, personalized treatment approaches. These advancements hold promise for improving IBS patient quality of life and reducing the disease burden on individuals and their families.

show abstract

Relationship Between Systemic Immune-Inflammation Index and Irritable Bowel Syndrome

Cited by 9 publications

References 29 publications

Systemic Immune-Inflammation Index as a Potential Biomarker for Assessing Disease Activity and Predicting Proteinuria Development in Systemic Lupus Erythematosus

Systemic Immune-Inflammation Index as a Potential Biomarker for Assessing Disease Activity and Predicting Proteinuria Development in Systemic Lupus Erythematosus

Clinical value of the systemic immune-inflammation index in moyamoya disease

Immune cell signatures and causal association with irritable bowel syndrome: A mendelian randomization study

Contact Info

Product

Resources

About